H&Q Life Sciences Investors
2 Liberty Square
9th Floor
Boston,
MA 02109
Phone: 617-772-8500
Fax: 617-772-8577
Web Site: http://www.hqcm.com/hql.aspx
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| H&Q Life Sciences Investors is a close ended equity mutual fund launched and managed by Hambrecht & Quist Capital Management, LLC. The fund invests in the public equity markets across the globe. It invests in stocks of companies operating in the health technology and life sciences industries. It also invests in stocks of early and later stage financings of privately held companies, private placements by public companies. The fund invests in growth stocks of companies operating across all market capitalizations. It employs fundamental analysis with a focus on factors such as potential for above-average, long-term growth in revenues and earnings securities strong market position for their services or products, experienced business management, and, recognized technological expertise. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. H&Q Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Dr. Daniel R. Omstead Ph.D., 56
Principal Exec. Officer, Pres, Trustee, Chief Exec. Officer of Hambrecht & Quist Capital Management Inc and Pres of Hambrecht & Quist Capital Management Inc |
$
0 | N/A | Ms. Laura F. Woodward ,
Chief Compliance Officer |
N/A
| N/A | Ms. Kathleen M. Eckert , 44
Principal Financial Officer |
N/A
| N/A | Ms. Carolyn P. Haley CPA, 43
Chief Compliance Officer, Sec. and Treasurer |
N/A
| N/A | Dr. Frank T. Gentile Ph.D., 48
Sr. VP of Research of Hambrecht & Quist Capital Management Incorporated |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.05 (0.52%)
Reuters offers more in-depth
